CN112741851A - Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules - Google Patents
Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules Download PDFInfo
- Publication number
- CN112741851A CN112741851A CN202110165308.1A CN202110165308A CN112741851A CN 112741851 A CN112741851 A CN 112741851A CN 202110165308 A CN202110165308 A CN 202110165308A CN 112741851 A CN112741851 A CN 112741851A
- Authority
- CN
- China
- Prior art keywords
- tea
- sparrow
- eutectic solvent
- extract
- tea extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 60
- 241000287127 Passeridae Species 0.000 title claims abstract description 50
- 239000002904 solvent Substances 0.000 title claims abstract description 45
- 230000005496 eutectics Effects 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000008187 granular material Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241001122767 Theaceae Species 0.000 title claims description 101
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- 238000000605 extraction Methods 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 25
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 238000002137 ultrasound extraction Methods 0.000 claims abstract description 12
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000004440 column chromatography Methods 0.000 claims abstract description 8
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 7
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 7
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 7
- 229960003178 choline chloride Drugs 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 4
- 229960001031 glucose Drugs 0.000 claims abstract description 4
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 229960005150 glycerol Drugs 0.000 claims abstract description 3
- 239000011347 resin Substances 0.000 claims abstract description 3
- 229920005989 resin Polymers 0.000 claims abstract description 3
- 238000000926 separation method Methods 0.000 claims abstract description 3
- 238000003756 stirring Methods 0.000 claims abstract description 3
- 235000013211 Adiantum capillus veneris Nutrition 0.000 claims description 16
- 241001148501 Adiantum pedatum Species 0.000 claims description 16
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 11
- 239000008101 lactose Substances 0.000 claims description 11
- 210000003323 beak Anatomy 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 229940092665 tea leaf extract Drugs 0.000 claims 2
- 244000269722 Thea sinensis Species 0.000 abstract 9
- 241000218691 Cupressaceae Species 0.000 abstract 1
- 244000007853 Sarothamnus scoparius Species 0.000 abstract 1
- 235000013616 tea Nutrition 0.000 description 90
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 31
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 30
- 229940116269 uric acid Drugs 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 7
- 229960003459 allopurinol Drugs 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 229950000193 oteracil Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- -1 10g of each part Substances 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000287227 Fringillidae Species 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 235000012511 Vaccinium Nutrition 0.000 description 2
- 241000736767 Vaccinium Species 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000015091 medicinal tea Nutrition 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 238000009740 moulding (composite fabrication) Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- 241001521402 Maackia <angiosperm> Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 235000002818 Vaccinium dunalianum Nutrition 0.000 description 1
- 241000733416 Vaccinium dunalianum Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000000571 coke Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Abstract
The invention provides a method for extracting a sparrow tea extract by a eutectic solvent method and preparation and application of granules of the sparrow tea extract, which comprise the following steps: s1, crushing the dried tea leaves with the sparrow mouth by using a crusher, transferring the crushed tea leaves to a container, and storing the crushed tea leaves in a dryer; s2, mixing one of 1, 4-butanediol, anhydrous glucose or glycerol and choline chloride according to a molar ratio of 1: 4-8, placing the mixture in a flask, performing oil bath, and continuously heating and stirring to prepare a eutectic solvent; s3, mixing the sparrow tea powder with the eutectic solvent according to the dosage of 20ml of eutectic solvent for every 1g of sparrow tea powder, and performing ultrasonic extraction for 30-60min at the temperature of 40-80 ℃; s4, performing column chromatography separation on the extracting solution by NKA-9 resin, eluting eutectic solvent in the components, and separating by using 95% ethanol to obtain the broom cypress tea extract. The invention has simple extraction process and convenient operation, shortens the extraction period and improves the extraction efficiency; the obtained tea extract can be used for preparing medicines for treating hyperuricemia and related diseases.
Description
[ technical field ] A method for producing a semiconductor device
The invention relates to a method for extracting a sparrow tea extract by a eutectic solvent method and preparation and application of granules.
[ background of the invention ]
Hyperuricemia is a metabolic disease caused by increased uric acid synthesis and/or decreased uric acid excretion, and refers to a non-twice-daily fasting blood uric acid level higher than 420 μmol/L under normal purine diet. Meta analysis is carried out on the hyperuricemia prevalence rate of Chinese population, and the result shows that the prevalence rate of hyperuricemia of men and women in Chinese population is 21.6 percent and 8.6 percent respectively, the total prevalence rate is 13.3 percent, and the prevalence number exceeds 1.3 hundred million.
Uric acid, as the end product of purine metabolism, is synthesized in other tissues such as liver, intestinal tract and muscle, kidney and vascular endothelium mainly by the catalytic action of xanthine oxidase, two thirds of which are excreted via the renal uric acid transporter, and the remaining third of which is excreted to the intestinal tract. At present, the clinical uric acid lowering drugs mainly aim at the production and excretion of uric acid, and comprise three types of drugs for inhibiting xanthine oxidase, promoting uric acid excretion and uricase for decomposing uric acid. Drugs used clinically have side effects of different degrees, and the search and development of novel uric acid lowering drugs are urgent works.
Tea (Vaccinium dunalinum W.) is terminal bud or tender leaf of Vaccinium dunalianum (V.dunalinum) belonging to Vaccinium of Ericaceae. The appearance is similar to that of a bird beak, the soup color is orange yellow and bright, the fragrance is mellow, the aftertaste is sweet, the tea is mainly distributed in the area of Yunan Chuxiong, and the tea has the effects of reducing blood fat, blood sugar and blood pressure, tonifying spleen, stimulating appetite, relaxing bowels, moistening intestines, resisting oxidation, radically ventilating, dispelling wind, removing dampness, relaxing tendons, activating collaterals and the like when being drunk frequently. Research shows that the Maackia tea contains a large amount of biological active ingredients such as the uridine, the arbutin, the chlorogenic acid, the caffeic acid, the caffeoylquinic acid and the like. The Quezui tea is a good product for Ming dynasty to pay and is widely drunk in Dian as a health-care tea for treating hyperuricemia and gout in folk.
At present, the extraction of the sparrow tea mostly uses the traditional natural plant extraction technology, mainly adopts organic solvents such as methanol, ethanol and the like for extraction, and the research of using green and safe solvents as the solvents is quite limited. The conventional extraction methods have the problems that the solvent has toxicity and remains in the extract, the subsequent removal process is complicated, the extraction efficiency is low, the extraction time is long, the solvent volatilization or discharge in the preparation process can pollute the environment, and the solvent is not easy to degrade after being used. The practical development and utilization of the sparrow mouth tea are limited by the above varieties. The novel extraction method is developed, and the sparrow mouth tea is extracted by using the eutectic method, so that the extraction efficiency of the uric acid reducing component of the sparrow mouth tea is improved, the production benefit is improved, and the environment is protected.
In addition, no report is found on the method for preparing granules from the extract of the tea leaves of the sparrow beak at present and the application of the extract in treating hyperuricemia.
In view of the above, the present invention is particularly proposed.
[ summary of the invention ]
The invention aims to solve one of the technical problems and provides a method for extracting a tea extract from sparrow tea by a eutectic solvent method, which has the advantages of simple extraction process, convenience in operation, shortened extraction period and improved extraction efficiency.
The present invention achieves one of the above technical problems:
a method for extracting a Quezui tea extract by a eutectic solvent method comprises the following steps:
s1, crushing the dried tea leaves with the sparrow mouth by using a crusher, transferring the crushed tea leaves to a container, and storing the crushed tea leaves in a dryer;
s2, mixing one of 1, 4-butanediol, anhydrous glucose or glycerol and choline chloride according to a molar ratio of 1: 4-8, placing the mixture in a flask, performing oil bath, and continuously heating and stirring to prepare a uniform and stable eutectic solvent;
s3, mixing the sparrow tea powder with the eutectic solvent according to the dosage of 20ml of eutectic solvent for every 1g of sparrow tea powder, and performing ultrasonic extraction for 30-60min at the temperature of 40-80 ℃;
s4, after extraction is finished, performing column chromatography separation on the extracting solution by NKA-9 resin, eluting eutectic solvent in the components, and separating by using 95% ethanol to obtain the maidenhair tea extract.
The second technical problem to be solved by the invention is to provide a preparation method of the granules of the tea extract of the maidenhair, the prepared tea granules of the maidenhair are more suitable for the current production requirements, the quality inspection method is convenient and easy to operate, and the product qualification rate is high.
The invention realizes the second technical problem in the following way:
a preparation method of a sparrow tea extract granule is provided, wherein the sparrow tea extract is extracted by the method for extracting the sparrow tea extract based on the eutectic solvent method; the preparation method comprises the following steps:
mixing the obtained thick tea extract with starch and lactose in a mass ratio of 2: 1:1, adding 60% ethanol as a wetting agent, making into soft material, holding with hand, making into mass, dispersing under light pressure, sieving with 14 mesh sieve, drying at 45 deg.C for 5 hr, and grading.
The third technical problem to be solved by the invention is to provide an application of the tea extract, namely the application of the tea extract in preparing medicines for treating hyperuricemia and related diseases. The invention has the following advantages:
the used eutectic solvent is simple to synthesize and low in raw material price; the extraction process is simple, the operation is convenient, the extraction period is shortened, and the extraction efficiency is improved; the treatment energy consumption is reduced, and the method is convenient and economical; the problems of time consumption and low extraction rate of the traditional process are avoided.
The active ingredients of the sparrow mouth tea are fully extracted by the eutectic solvent method, and are made into granules convenient to eat and store, so that a certain foundation is laid for new medicine sources; the prepared sparrow mouth tea granules are suitable for the current production requirements, the quality inspection method is convenient and easy to operate, and the product qualification rate is high.
The invention discloses a new application of a sparrow tea extract in preparing a medicine for treating hyperuricemia. The invention provides a new material basis, a preparation method and medical application of the tea extract of the maidenhair tea in treating hyperuricemia and related diseases (gout, uric acid renal calculus and the like).
[ description of the drawings ]
The invention will be further described with reference to the following examples with reference to the accompanying drawings.
FIG. 1 is a bar graph of the effect of different extracts of example 5 of the present invention on reducing serum uric acid in hyperuricemic mice.
FIG. 2 is a bar graph of the effect of different extracts on serum creatinine levels in example 5 of the present invention.
FIG. 3 is a bar graph of the effect of different extracts on serum urea nitrogen levels in example 5 of the present invention.
FIG. 4 is a schematic representation of the effect of different extracts on kidney histology in example 5 of the present invention, wherein the main panels are H & E staining, 100 ×; the upper right panel is stained with H & E, 200 ×.
[ detailed description ] embodiments
The technical solution of the present invention will be described clearly and completely with reference to the accompanying drawings and the detailed description. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
1. Extraction of active ingredients
Example 1
1) The choline chloride and the anhydrous glucose are weighed according to the molar ratio of 1:4, and the natural eutectic solvent (the water content is 10%) is prepared.
2) The obtained natural eutectic solvent is used for extracting the tea powder of the maidenhair tea, and the uric acid reducing component is extracted from the tea powder of the maidenhair tea, wherein the extraction method comprises the following steps:
3) mixing 20ml of eutectic solvent and 1g of sparrow tea powder uniformly, performing ultrasonic extraction at 40 ℃, wherein the power of an ultrasonic extractor is 500W in the ultrasonic extraction process, the extraction time is 10 minutes, and filtering the obtained mixture.
4) Eluting the low eutectic solvent in the filtrate by column chromatography, and separating with 95% ethanol to obtain the component of herba Caraganae Sinicae.
Example 2
1) Weighing choline chloride and glycerol according to a molar ratio of 1:4 to prepare a natural eutectic solvent (with the water content of 10%);
2) the obtained natural eutectic solvent is used for extracting the tea powder of the maidenhair tea, and the uric acid reducing component is extracted from the tea powder of the maidenhair tea, wherein the extraction method comprises the following steps:
3) mixing 20ml of eutectic solvent and 1g of sparrow tea powder uniformly, performing ultrasonic extraction at 50 ℃, wherein the power of an ultrasonic extractor is 500W in the ultrasonic extraction process, the extraction time is 20 minutes, and filtering the obtained mixture.
4) Eluting the low eutectic solvent in the filtrate by column chromatography, and separating with 95% ethanol to obtain the extract component of herba Caraganae Sinicae.
Example 3
1) The natural eutectic solvent (water content of 10%) is prepared by weighing choline chloride and 1, 4-butanediol according to a molar ratio of 1: 4.
2) The obtained natural eutectic solvent is used for extracting the tea powder of the maidenhair tea, and the uric acid reducing component is extracted from the tea powder of the maidenhair tea, wherein the extraction method comprises the following steps:
3) mixing 20ml of eutectic solvent and 1g of sparrow tea powder uniformly, performing ultrasonic extraction at 60 ℃, wherein the power of an ultrasonic extractor is 500W in the ultrasonic extraction process, the extraction time is 25 minutes, and filtering the obtained mixture.
4) Eluting the low eutectic solvent in the filtrate by column chromatography, and separating with 95% ethanol to obtain the extract component of herba Caraganae Sinicae.
Example 4
1) The natural eutectic solvent (water content is 10%) is prepared by weighing choline chloride and 1, 4-butanediol according to the molar ratio of 1: 8.
2) The obtained natural eutectic solvent is used for extracting the tea powder of the maidenhair tea, and the uric acid reducing component is extracted from the tea powder of the maidenhair tea, wherein the extraction method comprises the following steps:
3) mixing 20ml of eutectic solvent and 1g of sparrow tea powder uniformly, performing ultrasonic extraction at 80 ℃, wherein the power of an ultrasonic extractor is 500W in the ultrasonic extraction process, the extraction time is 30 minutes, and filtering the obtained mixture.
4) Eluting the low eutectic solvent in the filtrate by column chromatography, and separating with 95% ethanol to obtain the component of herba Caraganae Sinicae.
Comparative example 1
Comparative example 1 is a conventional methanol extraction process, as follows:
1) pulverizing Chinese medicinal tea of fructus Caraganae Sinicae with pulverizer to obtain powder of fructus Caraganae Sinicae tea.
2) Extracting 500g of the tea powder prepared in the step 1) with 60% methanol water for 3 times, soaking for 24 hours each time, wherein the material-liquid ratio is 1:2, filtering, combining the filtrates, pouring into a pot, evaporating and concentrating on an induction cooker to obtain extract, weighing and recording the weight of the obtained extract.
Comparative example 2
Comparative example 1 is a conventional ethanol extraction process, as follows:
1) pulverizing Chinese medicinal tea of fructus Caraganae Sinicae with pulverizer to obtain powder of fructus Caraganae Sinicae tea.
2) Extracting 500g of the tea powder prepared in the step 1) with 60% methanol water for 3 times, soaking for 24 hours each time, wherein the material-liquid ratio is 1:2, filtering, combining the filtrates, pouring into a pot, evaporating and concentrating on an induction cooker to obtain extract, weighing and recording the weight of the obtained extract.
2. Calculating the extraction rate of the sparrow mouth tea
The extraction rates of the sparrow tea in the examples and the comparative examples are calculated, and the yield of the uric acid reducing target component of the sparrow tea in the examples and the comparative examples is determined by using an HPLC method.
The detection results of the high performance liquid chromatography detection results of the uric acid reducing components of the tea leaves of sparrow mouths obtained in the examples and the comparative examples are shown in the table 1.
Table 1: high performance liquid chromatography detection results of uric acid-reducing target components obtained in examples and comparative examples
As can be seen from Table 1, the uric acid reducing component extracted from the tea leaves of the sparrow mouths has higher yield than that of the traditional extraction method.
3. Preparation of granules
Screening a prescription: respectively selecting common auxiliary materials, namely starch, lactose, CMC-Na, dextrin and mannitol, and extracting: mixing adjuvants at a certain proportion, adding appropriate amount of wetting agent 60% ethanol to make soft material, sieving with 14 # sieve, drying at 45 deg.C in constant temperature drying oven for 5 hr, sieving, and grading.
Mixing 5 parts of the extract, 10g of each part, starch, lactose, CMC-Na, dextrin, mannitol and other auxiliary materials, namely the Mazu tea extract, in a ratio of 1:1, and granulating.
Table 2: screening of prescription adjuvants
As can be seen from table 2, the granulation effect of starch and dextrin was higher than that of other adjuvants by the evaluation of the one-shot forming rate through the experiment; the flowability of the granulation of starch and lactose is best; the starch and CMC-Na are granulated and have poor dissolubility, and more precipitates are formed after the starch and the CMC-Na are dissolved and stood; the mannitol granulation has more fine powder, lower adhesion, loose granules and poorer hardness. Finally selecting starch and lactose as a filler and a binder respectively through experimental investigation, and further investigating and optimizing the ratio of the starch and the lactose.
Mixing lactose and dextrin at ratio of 1:5, 1:2, 1:1, 2:1, and 5:1, and mixing with the extract at ratio of 1:1
Table 3: screening of prescription mixing auxiliary material proportion
As can be seen from Table 3, the soft mass prepared from the extract, starch and lactose in a ratio of 2:1 produced granules with good shape, suitable color and highest granulation rate.
4. Quality inspection
Appearance: the prepared sparrow mouth tea granules have consistent color, uniform weight, no agglomeration and no softening phenomenon.
Particle size (primary molding ratio): unless otherwise specified, the resulting tea granules were measured by passing through a sieve of one size (200 μm) and a sieve of five size (180 μm), respectively, according to the examination of particle size and particle size distribution, and it was required that the sum of the amount of the tea granules which could not pass through the sieve of one size and the amount of the tea granules which could pass through the sieve of five size should not exceed 15% of the amount to be supplied.
Solubility: 10g of the test sample is taken, 200mL of warm water is added, the mixture is stirred for 5 minutes, and the mixture is immediately observed to be completely dissolved or slightly turbid. The above method can be used for detecting that no foreign matter is obtained, and no charred powder is obtained.
Moisture content: the water content of the product should not exceed 8.0% unless otherwise specified, as determined by moisture determination.
Loss on drying: unless otherwise specified, the chemical and biological granules are dried at 105 deg.C (the sugar-containing granules should be dried at 80 deg.C under reduced pressure) to constant weight, and the weight loss should not exceed 2.0%, as determined by the method of drying weight loss.
In conclusion, the optimal preparation process of the Quezui tea granules is as follows:
s1, crushing the maidenhair tea by using a crusher, mixing 20ml of 1, 4-butanediol-choline chloride serving as an eutectic solvent under the condition of heating to 80 ℃ in an oil bath, adding a proper amount of maidenhair tea powder for ultrasonic extraction, filtering the obtained mixture, recovering the eutectic solvent through column chromatography, and separating by using ethanol to obtain a maidenhair tea component;
s2, mixing the obtained dense extract of the tea leaves with starch and lactose in a mass ratio of 2: 1:1, adding 60% ethanol as a wetting agent, making into soft material, holding with hand, making into mass, dispersing under light pressure, sieving with 14 mesh sieve, drying at 45 deg.C for 5 hr, and grading. And (4) carrying out quality inspection on the prepared granules.
The quality inspection result of the sparrow mouth tea granules is as follows:
the sparrow mouth tea granules have consistent color, uniform weight, no agglomeration and no softening phenomenon; the molding rate is preferably up to 84% based on the ratio of starch to lactose of 1: 1; the dissolubility is carried out according to a standard method, and the test sample is completely dissolved without foreign matters and coke breeze; the water content is less than 8.0 percent; after drying weight loss, the loss mass is less than 2.0 percent; all meet the standard.
Example 5
The tea extract reduces the serum Uric Acid (UA) level of mice with hyperuricemia models and improves the renal inflammatory condition of mice with hyperuricemia models
Experimental materials: ICR mice were purchased from wus laboratory animals ltd, minhou county, fujian province. Potassium Oxonate, hypoxanthine, allopurinol, available from Sigma Aldrich (Sigma-Aldrich, Germany). Sodium carboxymethylcellulose was purchased from national pharmaceutical group chemical reagents, ltd. The uric acid kit is purchased from Nanjing to build Biotechnology Ltd.
Solution preparation: dissolving 1% sodium carboxymethylcellulose, boiling, cooling, and dissolving herba Bluestone extract, potassium oxonate, hypoxanthine and allopurinol to obtain suspension.
Grouping experiments: after being adaptively fed in an animal room for 7 days, 60 male ICR mice were randomly divided into 6 groups according to body weight, namely a normal group, a model group, a positive control group (allopurinol 10mg/kg/d), a low, medium and high dosage group (125, 250, 500mg/kg/d) of the extract of the tea finch, and 10 mice in each group.
Experimental treatment: mice were housed in a mouse house for 7 days to acclimatize, 1-5 groups were gavaged with hypoxanthine 500mg/kg and oteracil potassium 100mg/kg at 9 am for 21 consecutive days daily, and normal control groups were given with distilled water in equal amounts. On days 22-36, gavage hypoxanthine 500mg/kg and oteracil potassium 100mg/kg were administered as usual at 9 am, in groups 1-3 (low, medium, and high total extract dose groups) and 4 (allopurinol group) at 15 pm, gavage was administered at different doses, and in groups 5 (model group) and 6 (blank control group), the same amount of physiological saline was administered.
After molding for 1 hour, after ether inhalation anesthesia, the heart is bled, supernatant is sucked after centrifugation at 4000rpm for 10min, serum is stored in a refrigerator at 4 ℃ until detection, and the content detection is carried out according to the kit instruction by using the content detection of uric acid, urea nitrogen and creatinine in the serum. The mice were sacrificed after blood collection, the livers and kidneys of the mice were rapidly collected on ice, split-packed and frozen in liquid nitrogen before being immediately stored in a refrigerator at-80 ℃. HE staining of mouse kidney tissue was performed according to standard methods.
The experimental results are as follows:
1. change in serum uric acid: the mouse with hyperuricemia is subjected to intragastric administration by using 10mg/kg/d allopurinol and low, medium and high dosage groups (125, 250 and 500mg/kg/d) of the tea extract of the sparrow beak. The experimental results are shown in fig. 1, and compared with the blank control group, the serum uric acid of the model group is obviously increased, which indicates that the molding is successful. The low, medium and high dose groups of the sparrow tea extract reduce the serum uric acid level in a dose-dependent manner after being administrated for 2 weeks. (Note, # P < 0.001 compared to the blank control group; and # P < 0.001 compared to the model group).
2. Change in serum creatinine: the mouse with hyperuricemia is subjected to intragastric administration by using 10mg/kg/d allopurinol and low, medium and high dosage groups (125, 250 and 500mg/kg/d) of the tea extract of the sparrow beak. The experimental results are shown in fig. 2, and compared with the blank control group, the serum creatinine of the model group is obviously increased. And the low, medium and high dose groups of the tea finch extract reduce the serum creatinine level in a dose-dependent manner after being administered for 2 weeks. (Note, # P < 0.001 compared to the blank control group; P < 0.001; P < 0.005 compared to the model group).
3. Change in serum urea nitrogen: the mouse with hyperuricemia is subjected to intragastric administration by using 10mg/kg/d allopurinol and low, medium and high dosage groups (125, 250 and 500mg/kg/d) of the tea extract of the sparrow beak. The experimental results are shown in fig. 3, and compared with the blank control group, the serum urea nitrogen of the model group is obviously increased. And the low, medium and high dose groups of the tea extract of the sparrow beak show dose-dependent reduction of the level of serum urea nitrogen after being administrated for 2 weeks. (Note, # P < 0.001 compared to the blank control group; P < 0.001; P < 0.005 compared to the model group).
4. Pathological condition changes: when observed under an optical microscope, the cell nucleus is purple and the cytoplasm is red. As shown in fig. 4, the exudation and edema of inflammatory cells in the renal interstitium of the model group were significantly increased compared to the blank control group. The low, medium and high dose groups of the tea extract of the sparrow beak show that the exudation, edema and other conditions of inflammatory cells of renal interstitium are improved in a dose-dependent manner after the administration for 2 weeks.
In conclusion, the invention adopts a hyperuricemia mouse model to investigate the effect of the tea sparrow mouth extract on resisting hyperuricemia, particularly reducing the blood uric acid level. The results show that the blood serum uric acid level of the mice can be obviously reduced by the gastric lavage of the tea extract, so the tea extract has the effect of resisting hyperuricemia. The sparrow tea extract is taken as an active substance and is singly used or/and combined with other compounds and/or extracts with pharmacological activity for compound use, and then prepared into anti-hyperuricemia drugs and/or health care products with various dosage forms according to the conventional preparation method in the pharmaceutical field, or prepared into compound preparations with other uricosuric drugs and/or xanthine oxidase inhibitors and the like, so that the adverse reaction in the drug action is reduced under the condition of keeping the curative effect, and a safe, effective and economical solution is provided for the treatment, prevention and treatment of hyperuricemia.
It should be noted that the tea extract of the invention can be applied to the treatment of hyperuricemia, and can also be applied to the treatment of diseases related to hyperuricemia, such as gout, uric acid renal calculus, and the like.
Although specific embodiments of the invention have been described above, it will be understood by those skilled in the art that the specific embodiments described are illustrative only and are not limiting upon the scope of the invention, and that equivalent modifications and variations can be made by those skilled in the art without departing from the spirit of the invention, which is to be limited only by the appended claims.
Claims (3)
1. A method for extracting a sparrow tea extract by a eutectic solvent method is characterized by comprising the following steps: the method comprises the following steps:
s1, crushing the dried tea leaves with the sparrow mouth by using a crusher, transferring the crushed tea leaves to a container, and storing the crushed tea leaves in a dryer;
s2, mixing one of 1, 4-butanediol, anhydrous glucose or glycerol and choline chloride according to a molar ratio of 1: 4-8, placing the mixture in a flask, performing oil bath, and continuously heating and stirring to prepare a uniform and stable eutectic solvent;
s3, mixing the sparrow tea powder with the eutectic solvent according to the dosage of 20ml of eutectic solvent for every 1g of sparrow tea powder, and performing ultrasonic extraction for 30-60min at the temperature of 40-80 ℃;
s4, after extraction is finished, performing column chromatography separation on the extracting solution by NKA-9 resin, eluting eutectic solvent in the components, and separating by using 95% ethanol to obtain the maidenhair tea extract.
2. A preparation method of granules of a sparrow tea extract is characterized by comprising the following steps: the adopted tea extract of the sparrow beak is extracted based on the method of claim 1; the preparation method comprises the following steps:
mixing the obtained thick tea extract with starch and lactose in a mass ratio of 2: 1:1, adding 60% ethanol as a wetting agent, making into soft material, holding with hand, making into mass, dispersing under light pressure, sieving with 14 mesh sieve, drying at 45 deg.C for 5 hr, and grading.
3. The application of the sparrow tea extract is characterized in that: the tea leaf extract is extracted based on the method of claim 1, and the application of the tea leaf extract in preparing medicines for treating hyperuricemia and related diseases is provided.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110165308.1A CN112741851A (en) | 2021-02-06 | 2021-02-06 | Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110165308.1A CN112741851A (en) | 2021-02-06 | 2021-02-06 | Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112741851A true CN112741851A (en) | 2021-05-04 |
Family
ID=75651853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110165308.1A Pending CN112741851A (en) | 2021-02-06 | 2021-02-06 | Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112741851A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113332194A (en) * | 2021-05-21 | 2021-09-03 | 西南林业大学 | Method for preparing sparrow mouth tea extract by microwave-subcritical water extraction |
| WO2024049882A1 (en) * | 2022-09-01 | 2024-03-07 | Performance Labs PTE. LTD. | Bioactive extraction method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106038670A (en) * | 2016-07-20 | 2016-10-26 | 高志奎 | Preparation method of Vaccinium dunalianum Wight extract |
| CN111040006A (en) * | 2019-12-31 | 2020-04-21 | 云南大学 | Extraction method of bilberry glycoside and application of bilberry glycoside |
| CN111471078A (en) * | 2020-05-14 | 2020-07-31 | 华侨大学 | Preparation method of uridine in tea with sparrow mouth and application of uridine in treatment of hyperuricemia |
| CN111533770A (en) * | 2020-05-14 | 2020-08-14 | 华侨大学 | Preparation method of arbutin in sparrow tea and application of arbutin in treating hyperuricemia |
-
2021
- 2021-02-06 CN CN202110165308.1A patent/CN112741851A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106038670A (en) * | 2016-07-20 | 2016-10-26 | 高志奎 | Preparation method of Vaccinium dunalianum Wight extract |
| CN111040006A (en) * | 2019-12-31 | 2020-04-21 | 云南大学 | Extraction method of bilberry glycoside and application of bilberry glycoside |
| CN111471078A (en) * | 2020-05-14 | 2020-07-31 | 华侨大学 | Preparation method of uridine in tea with sparrow mouth and application of uridine in treatment of hyperuricemia |
| CN111533770A (en) * | 2020-05-14 | 2020-08-14 | 华侨大学 | Preparation method of arbutin in sparrow tea and application of arbutin in treating hyperuricemia |
Non-Patent Citations (2)
| Title |
|---|
| MARIANA RUESGAS-RAMON，等: "Application of Deep Eutectic Solvents (DES) for Phenolic Compounds Extraction: Overview, Challenges, and Opportunities", 《JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY》 * |
| 聂飞等: "贵州野生越桔种质资源及其开发利用", 《亚热带植物科学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113332194A (en) * | 2021-05-21 | 2021-09-03 | 西南林业大学 | Method for preparing sparrow mouth tea extract by microwave-subcritical water extraction |
| WO2024049882A1 (en) * | 2022-09-01 | 2024-03-07 | Performance Labs PTE. LTD. | Bioactive extraction method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106668657A (en) | Beverage capable of lowering uric acid and lipid and preparation method of beverage | |
| CN102015746A (en) | Compositions comprising galactomannan and a process thereof | |
| CN112741851A (en) | Method for extracting sparrow tea extract by eutectic solvent method and preparation and application of granules | |
| CN111533770A (en) | Preparation method of arbutin in sparrow tea and application of arbutin in treating hyperuricemia | |
| CN111471078A (en) | Preparation method of uridine in tea with sparrow mouth and application of uridine in treatment of hyperuricemia | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN108186803A (en) | The preparation process of compound oral liquid for tonifying blood containing red skin of peanut | |
| CN114832022A (en) | Preparation of phellinus igniarius sporocarp phenolic active substance and application of phellinus igniarius sporocarp phenolic active substance in regulation of intestinal flora and uric acid metabolism | |
| CN107865930A (en) | A kind of pine pollen composition and its preparation method and application | |
| CN106109488A (en) | The application in preparing the food or medicine with blood fat reducing function of a kind of Quinoa polysaccharide | |
| CN104013733B (en) | Chitosan composition for prevention and treatment of chemical liver injury and preparation method thereof | |
| CN106421208B (en) | Pharmaceutical composition with chemical liver injury resistance function and preparation method thereof | |
| CN107537028B (en) | Formula for simultaneously assisting in reducing blood sugar and blood pressure and preparation method thereof | |
| CN109771457A (en) | Purposes of the russule extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease | |
| CN101804083B (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| CN105920051B (en) | Flammulina velutipes extract and preparation method and application thereof | |
| WO2021174801A1 (en) | Method for preparing antrodia cinnamomea water-insoluble dietary fibers | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN106928376A (en) | The separation method of skunk bush polysaccharide and its application | |
| CN103054906A (en) | Propolis ethanol extract for alleviating hangover and preparation method thereof, and application of propolis ethanol extract in producing buccal tablets | |
| CN102309705A (en) | Medicine for reducing serum uric acid, preparation method thereof and purpose thereof | |
| CN101491645A (en) | Medicine preparation for treating diabetes and complicating disease thereof and preparation method thereof | |
| CN101757059A (en) | Method for extracting alpha-glucosidase activity inhibitor from plants | |
| CN101167887A (en) | Orally-administered matrimony vine single preparation traditional Chinese medicine for treating diabetes and preparation method thereof | |
| CN101804128B (en) | Medicine composition, and use thereof in preparing medicine for curing inflammatory enteropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210504 |
|
| RJ01 | Rejection of invention patent application after publication |